Human coronavirus 229E (HCoV-229E), a causative agent of the common cold, enters host cells 17 via two distinct pathways: one is mediated by cell surface proteases, particularly transmembrane 18 protease serine 2 (TMPRSS2), and the other by endosomal cathepsin L. Thus, specific inhibitors 19 of these proteases block virus infection. However, it is unclear which of these pathways is 20 actually utilized by HCoV-229E in the human respiratory tract. Here, we examined the 21 mechanism of cell entry used by a pseudotyped virus bearing the HCoV-229E spike (S) protein 22 in the presence/absence of protease inhibitors. We found that, when compared with a laboratory 23 strain isolated in 1966 and passaged for a half century, clinical isolates of HCoV-229E were less 24 likely to utilize cathepsin L; rather, they showed a preference for TMPRSS2. Two amino acid 25 substitutions (R642M and N714K) in the S protein of HCoV-229E clinical isolates altered their 26 sensitivity to a cathepsin L inhibitor, suggesting that these amino acids were responsible for 27 cathepsin L use. After 20 passages in HeLa cells, the ability of the isolate to use cathepsin 28 increased such that it was equal to that of the laboratory strain; this increase was caused by an 29 amino acid substitution (I577S) in the S protein. The passaged virus showed a reduced ability to 30 replicate in differentiated airway epithelial cells cultured at an air-liquid interface. These results 31 suggest that the endosomal pathway is disadvantageous for HCoV-229E infection of human 32 airway epithelial cells; therefore, clinical isolates are less able to use cathepsin. 33 34 IMPORTANCE 35 Many envelope viruses enter cells through endocytosis. Viral spike proteins drive the fusion of 36 viral and endosomal membranes to facilitate insertion of the viral genome into the cytoplasm.
INTRODUCTION
causative agent of the human common cold. HCoV-229E was first reported in 1966 (1), and the 7 min at 37°C. Approximately 10 2 to 10 3 FFU of VSV-pseudotyped virus harboring the 115 HCoV-229E S protein was inoculated onto the cells in the presence of the inhibitors, and the 116 cells were incubated at 37°C for 20 h. Dimethyl sulfoxide (DMSO)-treated cells served as 117 negative (no inhibitor) controls. After incubation, images were captured under a BZ8000 118 microscope (Keyence Corporation, Osaka, Japan) and GFP-positive cells were counted using 119 image measurement and analysis software (VH-H1A5 version 2.6; Keyence). The inhibitory 120 effect was expressed as a percentage value relative to control cells, as previously described (16) . 121 To examine the kinetics of cell entry, VSV-pseudotyped viruses were inoculated onto HeLa or 122 HeLa-TMPRSS2 cells on ice for 1 h and then incubated at 37°C. After the indicated times (0, 10, 123 20, 40, 60, 120, or 240 min), cells were treated with E64d or camostat (final concentration, 10 124 µM) to stop viral entry. After 24 h, the number of GFP-positive cells was counted and data were 125 expressed as a percentage relative to those in HeLa-TMPRSS2 cells. 8 value.
138
Quantification of viral and cellular RNA. HBTE cells were cultured in differentiation medium 139 (LIFELINE CELL TECHNOLOGY) for 0 or 4 weeks at an ALI in a Transwell chamber, and 140 cellular RNA was isolated by addition of ISOGEN reagent (Nippon Gene). HBTE cells were 141 then inoculated with HCoV-229E (10 4 PFU) or human coronavirus HKU1 (HCoV-HKU1; virus 142 titer not quantified) for 2 h and washed three times prior to incubation at 37°C at the ALI. To HeLa-TMPRSS2 cells was almost equal (Fig. 1A) , we confirmed that replication of clinical 170 isolates in native HeLa cells was 1 log less than that of the laboratory strain ( Fig. 1A) . To clarify or endosome, respectively (15, 16) . Cells were treated for 30 min with E64d, a broad inhibitor of 187 cysteine proteases (including cathepsins), and camostat, a serine protease inhibitor that inhibits 188 TMPRSS2, and then infected with pseudotyped viruses. Data were represented as percentage 189 blockade relative to that in cells not treated with inhibitors ( Fig. 2A and 2B ). As expected, 190 camostat had no effect on viral entry into HeLa cells, whereas E64d blocked entry of both 191 229E/lab and 229E/clin ( Fig. 2A ), suggesting that these viruses use only cathepsin L in this cell 192 line. By contrast, treatment of HeLa-TMPRSS2 cells with 5 μM E64d blocked 50% of 229E/lab, 193 but only 10% of 229E/clin, whereas treatment with camostat blocked 30% of 229E/lab, but 50% 194 of 229E/clin ( Fig. 2A) . These data suggest that 229E/clin tends to use TMPRSS2 rather than 195 cathepsin L, and that 229E/lab does the opposite. Figure 2B also shows a similar effect in that HCoV-229E is less able to utilize cathepsin in vivo, and that its ability to do so increases 258 upon serial passage in cultured cells. To confirm this experimentally, first-passage 259 229E/clin-Sd-p1 was passaged a further 19 times in HeLa cells to generate 229E/clin-p20. The 260 proliferation of 229E/clin-Sd-p1 in HeLa cells was 1 log less than that of 229E/lab, although the 261 viruses grew equally well in HeLa-TMPRSS2 cells (Fig. 4A) . After 20 passages, 262 229E/clin-Sd-p20 acquired a high capacity to replicate in HeLa cells (equivalent to that of 263 229E/lab) (Fig. 4A ). Analysis revealed a single point mutation (I577S) in the S protein.
264
Experiments using pseudotyped virus bearing a mutated S protein confirmed that I577S 265 increased viral entry into HeLa cells (Fig. 4B ). Entry of 229E/lab into HeLa cells was about 60% 266 of that into HeLa-TMPRSS2 cells, whereas that of 229E/clin-Sd-p1 was about 20%; furthermore, 267 a single mutation (I577S) in the 229E/clin-Sd S protein recovered virus entry by 60%; this 268 recovered entry was inhibited by treatment with cathepsin L inhibitor III (Fig. 4B ). However, 269 when we passaged 229E/clin-Sd in HeLa-TMPRSS2 cells, we did not observe enhanced 270 replication in HeLa cells or any mutations in the S protein.
272
The virus passaged in HeLa cells reduces infectivity in HBTE-ALI cells. We hypothesized 273 that the cathepsin/endosomal pathway may be disadvantageous for HCoV-229E in that reliance 274 on cathepsin would result in low replication in airway epithelial cells. Therefore, we prepared 275 on October 16, 2016 by CORNELL UNIVERSITY http://jvi.asm.org/ Downloaded from 14 differentiated primary HBTE cells using an ALI culture system, as described previously (15, 26) . 276 This is the best in vitro model of human airway epithelium (21). To confirm cell differentiation,
277
HBTE cells were inoculated with HCoV-HKU1 (which replicates only in differentiated airway 278 epithelial cells) (26). After 24 h, virus secreted on the apical surface was quantified by real-time 279 PCR. The results revealed a 60,000-fold increase in the amount of viral RNA (Fig. 5A) . We then HCoV-229E receptor) increased by 13-fold and 4-fold, respectively (Fig. 5B ). There was no 285 increase in mRNA encoding E-cadherin and ZO-1 (involved in the formation of tight junctions), 286 nor in mRNAs encoding TMPRSS2 or cathepsin L (Fig. 5B) .
287
To compare the replication of 229E/clin-Sd at passages 1 and 20, differentiated HBTE cells and 288 HeLa cells were inoculated with 10 4 PFU of virus, which was measured in a plaque assay using that affect cathepsin use are scattered randomly throughout the S2 subunit; none are close to the 303 protease cleavage site ( Fig. 6B and 6C) . The results of this study suggest that HCoV-229E behaves differently in cell culture than in the 307 human respiratory tract. We found that, compared with the strain reported in 1966 (229E/lab; 308 ATCC VR-740), HCoV-229E clinical strains isolated in 2004 (229E/clin-Sd; Sendai-H/1121/04) 309 and 2008 (229E/clin-Ng; Niigata/01/08) are less able to utilize endosomal cathepsin L for cell 310 entry. In the original paper from 1966, the first cytopathic effects of HCoV-229E were observed 311 11 days after inoculation onto cultured cells in the absence of trypsin (1). The virus presumably 312 acquired the ability to utilize cathepsin during the first isolation step or after passage over half a 313 century. Here, virus passaged 20 times was also highly able to use cathepsin. Interestingly, the 314 passaged virus was less able to replicate in differentiated airway epithelial cells, implying that 315 the endosomal pathway is disadvantageous for virus replication in vivo. As shown in Figure 2 , in 
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